"Merck Cuts Price of AIDS Drug"
Financial Times (03/20/97) P. 8; Green, Daniel
The price of the AIDS drug Crixivan will be cut by 9 percent
in the United Kingdom to bring the price down to the level charged
in other European Union countries, the drug’s maker, Merck, has
announced. Parallel importing, in which drugs are purchased in
countries where prices are lower and sold in other countries at
higher prices, is widespread in Europe and is opposed by the
pharmaceutical industry. Merck’s price adjustment "reflects our
continued faith in the single market for pharmaceuticals in Europe
and the likely introduction of a single European currency within a
few years," said Per Wold Olsen, Merck’s president of human health
for Europe. When Crixivan was introduced last year, Merck said it
would be sold at a uniform price across the European Union, which
the company claims to have achieved in "most" European nations.


27
Mar
Relief in the UK
posted by admin in Uncategorized and have Comment (1)



Archives
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
-
Recent Posts
- Democratic candidates avoiding comment on Michael Moore's proposals for universal healthcare.
- Women have higher risk of mid-life strokes
- hi
- By Francis DiMenno
- Advertised in Life. Ayds Reducing Plan Vitamin and Mineral Candy.
- misc.health.aids
- Personal Health Care Blog
- Losing friends
- HIV statistic lies from Kenya
- Hispanics are a new HIV target group







getw…@aol.com "Get Well" writes:
> "Merck Cuts Price of AIDS Drug"
> Financial Times (03/20/97) P. 8; Green, Daniel
> The price of the AIDS drug Crixivan will be cut by 9 percent
> in the United Kingdom to bring the price down to the level charged
> in other European Union countries, the drug’s maker, Merck, has
> announced.
They will have to give it away to reflect its true value as a
medicine, and even then wise prospects will refuse it altogether,
as so many do already.
John
—
Dr Ian Weller of University College, London, said the effects of
protease inhibitors were not known and he would be conservative
about prescribing them.
"You are actually committing people to many, many years of treatment
with combination drugs and you don’t know what the long-term effects
are." Reuters, Sept 10, 1996